ログイン
言語:

WEKO3

  • トップ
  • ランキング
To
lat lon distance
To

Field does not validate



インデックスリンク

インデックスツリー

メールアドレスを入力してください。

WEKO

One fine body…

WEKO

One fine body…

アイテム

  1. 広島大学の刊行物
  2. Hiroshima Journal of Medical Sciences
  3. 58巻1号

Induction of γδT Cells Using Zoledronate Plus Interleukin-2 in Patients with Metastatic Cancer

https://hiroshima.repo.nii.ac.jp/records/2013614
https://hiroshima.repo.nii.ac.jp/records/2013614
b3f7caee-b5a0-4b3d-a333-de600689b590
名前 / ファイル ライセンス アクション
HiroshimaJMedSci_58_37.pdf HiroshimaJMedSci_58_37.pdf (1.8 MB)
Item type デフォルトアイテムタイプ_(フル)(1)
公開日 2023-03-18
タイトル
タイトル Induction of γδT Cells Using Zoledronate Plus Interleukin-2 in Patients with Metastatic Cancer
言語 en
作成者 Nagamine, Ichiro

× Nagamine, Ichiro

en Nagamine, Ichiro

Search repository
Yamaguchi, Yoshiyuki

× Yamaguchi, Yoshiyuki

en Yamaguchi, Yoshiyuki

Search repository
Ohara, Masahiro

× Ohara, Masahiro

en Ohara, Masahiro

Search repository
Ikeda, Takuhiro

× Ikeda, Takuhiro

en Ikeda, Takuhiro

Search repository
Okada, Morihito

× Okada, Morihito

en Okada, Morihito

Search repository
アクセス権
アクセス権 open access
アクセス権URI http://purl.org/coar/access_right/c_abf2
権利情報
権利情報 (c) Hiroshima University Medical Press.
主題
主題Scheme Other
主題 γδT cells
主題
主題Scheme Other
主題 Zoledronate
主題
主題Scheme Other
主題 Interleukin-2
主題
主題Scheme Other
主題 Adoptive immunotherapy
主題
主題Scheme Other
主題 Cancer
主題
主題Scheme NDC
主題 490
内容記述
内容記述 A loss of human leukocyte antigen (HLA) expression in clinical tumors is one of their escape mechanisms from immune attack by HLA-restricted effector cells. In this study, the induction of HLA-unrestricted effector cells, γδT cells, using zoledronate (ZOL) and interleukin (IL)-2 in vitro was investigated in patients with metastatic cancer. Peripheral blood mononuclear cells (PBMCs) from 10 cancer patients (8 colorectal and 2 esophageal) with multiple metastases and ascites lymphocytes from 3 cancer patients (1 gastric and 2 colorectal) were stimulated with varied concentrations of ZOL plus 100 U/ml IL-2 for 48 hr followed by culturing with IL-2 alone for 12 days. Lymphocyte proliferative responses were determined using 3H-TdR uptakes and interferon (IFN)-γ production was evaluated using enzyme-linked immunosorbent assay. Surface phenotyping was performed using flow cytometry. Cytotoxic activity of effector cells was determined using 51Cr-releasing assay. It was found that proliferative responses of PBMCs were significantly stimulated with ZOL plus IL-2 when compared with IL-2 alone, showing 200 to 500-fold expansions for 2 weeks, although ZOL alone induced no response. The optimal concentration of ZOL was 1-5 μM. Ascites lymphocytes could also be stimulated with ZOL plus IL-2. The proliferative responses were remarkable in patients whose PBMCs could produce high levels ofIFN-γ during an initial 48-hr stimulation using ZOL plus IL-2. Removal of an adherent cell fraction before the induction augmented the proliferative responses in patients who otherwise had low-grade proliferative responses. Generated cells comprising approximately 90 or 20% in PBMCs from healthy donors or cancer patients, respectively, expressed γδ-type T-cell receptor. γδT cells showed high cytotoxic activity against CD166-positive TE12 and TE13 cancer cells but not against CD166-negative MKN45 cells. The cytotoxic activity against TE13 cells was augmented when target cells were pre-treated overnight with ZOL. These results suggest that ZOL in the presence of IL-2 can efficiently stimulate the proliferation of γδT cells, which have cytotoxic properties against cancer cells. The use of zoledronate-activated killer (ZAK) cells should be encouraged in possible adoptive immunotherapy trials for patients with incurable cancer.
言語 en
出版者
出版者 Hiroshima University Medical Press
言語
言語 eng
資源タイプ
資源タイプ識別子 http://purl.org/coar/resource_type/c_6501
資源タイプ departmental bulletin paper
出版タイプ
出版タイプ VoR
出版タイプResource http://purl.org/coar/version/c_970fb48d4fbd8a85
収録物識別子
収録物識別子タイプ ISSN
収録物識別子 0018-2052
収録物識別子
収録物識別子タイプ NCID
収録物識別子 AA00664312
開始ページ
開始ページ 37
書誌情報 Hiroshima Journal of Medical Sciences
Hiroshima Journal of Medical Sciences

巻 58, 号 1, p. 37-44, 発行日 2009-03
旧ID 34964
戻る
0
views
See details
Views

Versions

Ver.1 2025-02-23 06:38:29.584425
Show All versions

Share

Mendeley Twitter Facebook Print Addthis

Cite as

エクスポート

OAI-PMH
  • OAI-PMH JPCOAR 2.0
  • OAI-PMH JPCOAR 1.0
  • OAI-PMH DublinCore
  • OAI-PMH DDI
Other Formats
  • JSON
  • BIBTEX

Confirm


Powered by WEKO3


Powered by WEKO3